News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable Discussions
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
    • MS Advanced Practice Providers
  • Movement Disorders
    • Parkinson Disease
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
AANEM 2025|
ECTRIMS 2025|
MDS 2025
Advertisement

Lisa A. Brenner, PhD

Advertisement

Articles by Lisa A. Brenner, PhD

TBI and Suicide: From Science to Prevention Strategies

ByLisa A. Brenner, PhD,Riley P. Grassmeyer, MS,James P. Kelly, MD
May 1st 2019

Conceptualizing risk among patients with traumatic brain injury requires clinicians to consider multiple factors including neuroanatomic and cognitive dysfunction, and psychosocial impairment.

Advertisement

Latest Updated Articles

  • TBI and Suicide: From Science to Prevention Strategies
    TBI and Suicide: From Science to Prevention Strategies

    Published: May 1st 2019 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)

2

B-Cell Modulator Obexelimab Shows Pronounced Relapse Reduction in Phase 2 MoonStone Trial

3

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

4

Subcutaneous Efgartigimod Shows Efficacy in Phase 2 ALKIVIA, Phase 3 ADAPT SERON Trials

5

Independent Adjudication Committee Helps Facilitate Accurate Enrollment of Phase 2/3 ARISE Trial of Nipocalimab

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us